局部进展期乳腺癌不同方案新辅助化疗的临床研究
代志军;王西京;康华峰;王宁;刘小旭;薛兴欢;薛锋杰;纪宗正
【期刊名称】《中国现代医学杂志》 【年(卷),期】2006(016)014
【摘要】目的评价局部进展期乳腺癌的两种不同方案的新辅助化疗的近期疗效及其毒性反应.方法从2001年1月～2004年1月应用CEF、NEF两种不同化疗方案对68例局部进展期乳腺癌进行新辅助化疗.所有患者完成2个周期的新辅助化疗后评价疗效及毒性反应.结果原发灶有效率CEF、NEF两组分别为47.2%(17/36)和71.9%(23/32);其中各有1例病理完全缓解者,两组均无进展者.腋窝淋巴结有效率CEF、NEF两组分别为63.9%(23/36)和87.5%(28/32);新辅助化疗后CEF组有11例(30.6%),NEF组有17例(53.1%)未触及肿大淋巴结.两组均未见Ⅳ度毒性反应,白细胞下降、脱发及胃肠道反应两组程度相似.NEF组出现特有的神经毒性和周围静脉炎.结论两种不同方案用于局部进展期乳腺癌的新辅助化疗均有较好的近期疗效,毒性反应均可耐受.与CEF组相比,NEF组原发灶和腋窝淋巴结疗效均优于CEF组,而且两组毒性反应相当.%[Objective] To evaluate the efficacy and toxicity of two different regimens as neoadjuvant chemotherapy for local advanced breast cancer. [Methods] From January 2001 to January 2004, 68 patients with stage Ⅱb-Ⅲ breast cancer were treated with one of two different regimens: CEF, NEF, for 2 cycles every 28 days. Accroding to the effect standard and toxic grading standard suggested by WHO, efficacy and safety were evaluated after 2 cycles of neoadjuvant chemotherapy. Patients in CEF
regimen received combination of cyclophosphamide (CTX) 500mg/m2, d1, 8; epirubincin (EPI) 50 mg/m2, d1, 8; 5-fluorouracil (5-Fu) 500 mg/m2, d1, 8. Patients in NEF regimen received vinorelbine (NVB) 30 mg/m2, d1, 5; EPI 50 mg/m2, d1; 5-Fu 500 mg/m2, d1, 5. [Results] For primary tumor in the breast, the overall response rate (RR) was 47.2 % (17/36) in CEF regimen and 71.9 % (23/32) in NEF regimen. There was no disease progressive(PD) and one patient showed pathologic complete response (pCR) in both groups. For axillary lymph nodes, the overall response rate (RR) was 63.9 % (23/36) in CEF regimen and 87.5 %(28/32) in NEF regimen. Clinically palpable axillary lymph nodes which had been found in all 68 patients before treatment, 30.6 % (11/36) in CEF regimen and 53.1% (17/32) in NEF regimen became impalpable. The major toxicity, including leukopenia, gastroenteric reactions and alopecia were similar in both groups, but neurotoxicity and milieu phlebitis were the unique side-effects of the NEF regimen. [Conclusion] Neoadjuvant chemotherapy with two different regimens was all effective to the primary tumor and axillary metastatic lymph nodes of local advanced breast cancer, and the side effects were tolerable. Comparing with CEF, NEF regimen has higher efficacy and equal side effects.
【总页数】4页(2090-2093)
【关键词】乳腺肿瘤;新辅助化疗;临床疗效;不良反应
【作者】代志军;王西京;康华峰;王宁;刘小旭;薛兴欢;薛锋杰;纪宗正
【作者单位】西安交通大学医学院第二附属医院,肿瘤科,陕西,西安,710004;西安交通大学医学院第二附属医院,肿瘤科,陕西,西安,710004;西安交通大学医学院第二附属医院,肿瘤科,陕西,西安,710004;西安交通大学医学院第二附属医院,肿瘤科,陕西,西安,710004;西安交通大学医学院第二附属医院,肿瘤科,陕西,西安,710004;西安交通大学医学院第二附属医院,肿瘤科,陕西,西安,710004;西安交通大学医学院第二附属医院,肿瘤科,陕西,西安,710004;西安交通大学医学院第二附属医院,肿瘤科,陕西,西安,710004 【正文语种】中文 【中图分类】R737.9 【文献来源】
https://www.zhangqiaokeyan.com/academic-journal-cn_china-journal-modern-medicine_thesis/0201254003114.html 【相关文献】
1.局部进展期乳腺癌新辅助化疗3种方案的不良反应比较 [J], 代志军; 王西京; 刘小旭; 仵文英; 纪宗正; 康华峰; 薛锋杰; 薛兴欢
2.局部晚期乳腺癌两种不同方案新辅助化疗的临床疗效评价 [J], 代志军; 王西京; 康华峰; 管海涛; 纪宗正; 刘小旭; 薛锋杰; 薛兴欢
3.磁共振扩散加权成像表观扩散系数对局部进展期乳腺癌新辅助化疗的评估——不同测量方法比较 [J], 武春雪; 王霄英; 秦乃姗; 蒋学祥; 孙晓伟
4.TA新辅助化疗方案治疗局部进展期乳腺癌的有效性和安全性 [J], 王娅; 李孟圈; 郑世鹏
局部进展期乳腺癌不同方案新辅助化疗的临床研究
